THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Kathleen Moore to Molecular Targeted Therapy

This is a "connection" page, showing publications Kathleen Moore has written about Molecular Targeted Therapy.
Connection Strength

0.813
  1. Niraparib in the treatment of previously treated advanced ovarian, fallopian tubeĀ or primary peritoneal cancer. Future Oncol. 2020 Nov; 16(33):2701-2711.
    View in: PubMed
    Score: 0.653
  2. Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 09; 158(3):640-645.
    View in: PubMed
    Score: 0.160
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES